Rezolute, Inc. (RZLT)
4.53
-0.03
(-0.66%)
USD |
NASDAQ |
Sep 03, 16:00
4.53
0.00 (0.00%)
After-Hours: 20:00
Rezolute Research and Development Expense (TTM) : 59.77M for March 31, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | 59.77M |
| December 31, 2025 | 63.64M |
| September 30, 2025 | 61.92M |
| June 30, 2025 | 61.53M |
| March 31, 2025 | 59.75M |
| December 31, 2024 | 56.87M |
| September 30, 2024 | 56.28M |
| June 30, 2024 | 55.74M |
| March 31, 2024 | 47.59M |
| December 31, 2023 | 49.42M |
| September 30, 2023 | 48.32M |
| June 30, 2023 | 43.81M |
| March 31, 2023 | 41.45M |
| December 31, 2022 | 35.91M |
| September 30, 2022 | 34.42M |
| June 30, 2022 | 32.49M |
| March 31, 2022 | 28.30M |
| December 31, 2021 | 23.37M |
| September 30, 2021 | 18.42M |
| June 30, 2021 | 14.99M |
| March 31, 2021 | 13.04M |
| December 31, 2020 | 13.02M |
| September 30, 2020 | 13.56M |
| June 30, 2020 | 14.45M |
| March 31, 2020 | 13.72M |
| Date | Value |
|---|---|
| December 31, 2019 | 25.11M |
| September 30, 2019 | 21.38M |
| June 30, 2019 | 19.08M |
| March 31, 2019 | 24.42M |
| December 31, 2018 | 11.79M |
| September 30, 2018 | 13.90M |
| June 30, 2018 | 17.28M |
| March 31, 2018 | 13.31M |
| December 31, 2017 | 14.26M |
| September 30, 2017 | 13.92M |
| June 30, 2017 | 12.09M |
| March 31, 2017 | 11.65M |
| December 31, 2016 | 10.52M |
| September 30, 2016 | 9.966M |
| June 30, 2016 | 9.448M |
| March 31, 2016 | 8.534M |
| December 31, 2015 | 7.515M |
| September 30, 2015 | 6.557M |
| June 30, 2015 | 4.701M |
| March 31, 2015 | 3.002M |
| December 31, 2014 | 1.713M |
| September 30, 2014 | 0.1469M |
| June 30, 2014 | 0.0343M |
| March 31, 2014 | 0.0027M |
| December 31, 2013 | 0.0035M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| SELLAS Life Sciences Group, Inc. | 20.35M |
| AbbVie, Inc. | 9.714B |
| Marker Therapeutics, Inc. | 8.806M |
| Avalo Therapeutics, Inc. | 64.35M |
| Krystal Biotech, Inc. | 53.39M |